PL378360A1 - Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju - Google Patents

Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju

Info

Publication number
PL378360A1
PL378360A1 PL378360A PL37836004A PL378360A1 PL 378360 A1 PL378360 A1 PL 378360A1 PL 378360 A PL378360 A PL 378360A PL 37836004 A PL37836004 A PL 37836004A PL 378360 A1 PL378360 A1 PL 378360A1
Authority
PL
Poland
Prior art keywords
intraputaminal
infused
parkinson
humans
disease
Prior art date
Application number
PL378360A
Other languages
English (en)
Inventor
Steven S. Gill
Donald M. Gash
Greg Allen Gerhardt
Original Assignee
Amgen, Inc.
University Of Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen, Inc., University Of Kentucky filed Critical Amgen, Inc.
Publication of PL378360A1 publication Critical patent/PL378360A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL378360A 2003-02-24 2004-02-24 Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju PL378360A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44978903P 2003-02-24 2003-02-24
US10/784,547 US20040209810A1 (en) 2003-02-24 2004-02-23 Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor

Publications (1)

Publication Number Publication Date
PL378360A1 true PL378360A1 (pl) 2006-03-20

Family

ID=32930523

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378360A PL378360A1 (pl) 2003-02-24 2004-02-24 Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju

Country Status (8)

Country Link
US (1) US20040209810A1 (pl)
EP (1) EP1622636A2 (pl)
JP (1) JP2006518747A (pl)
AU (1) AU2004216251A1 (pl)
CA (1) CA2516857A1 (pl)
MX (1) MXPA05009011A (pl)
PL (1) PL378360A1 (pl)
WO (1) WO2004075720A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205772D0 (en) * 2002-03-12 2002-04-24 Gill Steven S Catheter
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
WO2006042090A1 (en) 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
JP5238503B2 (ja) * 2005-08-23 2013-07-17 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
PL2152346T3 (pl) * 2007-05-17 2016-04-29 Medgenesis Therapeutix Inc Cewnik do konwekcyjnie zwiększonej podaży leku z wyjmowanym usztywniającym elementem
JP6066035B2 (ja) * 2009-02-12 2017-01-25 クルナ・インコーポレーテッド グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
ES2363353B1 (es) * 2010-01-19 2012-02-22 Universidad De Sevilla Composición que comprende gdnf y tgf-beta1 y su uso para el tratamiento de una enfermedad neurológica.
PL2558154T3 (pl) 2010-04-16 2020-11-30 Clearpoint Neuro, Inc. Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
US20160263189A1 (en) * 2013-10-23 2016-09-15 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
WO2019216953A1 (en) 2018-05-09 2019-11-14 MRI Interventions, Inc. Mri compatible intrabody fluid transfer systems and related devices and methods
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
KR102519725B1 (ko) * 2022-06-10 2023-04-10 주식회사 하이 사용자의 인지 기능 상태를 식별하는 기법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2968840B2 (ja) * 1991-09-20 1999-11-02 サイナーゲン，インコーポレーテッド グリア由来神経栄養因子
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US7069634B1 (en) * 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
DE69735683T2 (de) * 1996-03-22 2006-10-19 Seiko Epson Corp. Vorrichtung zum Messen der Bewegungsintensität

Also Published As

Publication number Publication date
WO2004075720A2 (en) 2004-09-10
MXPA05009011A (es) 2006-04-07
WO2004075720A3 (en) 2004-11-11
EP1622636A2 (en) 2006-02-08
US20040209810A1 (en) 2004-10-21
AU2004216251A1 (en) 2004-09-10
JP2006518747A (ja) 2006-08-17
CA2516857A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
SI1835924T1 (sl) Zdravljenje Parkinsonove bolezni in sorodnih obolenj z uporabo celic, pridobljenih post partum
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
IL183772A0 (en) Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
AU2003233583A8 (en) Oral lactoferrin in the treatment of respiratory disorders
IL181706A0 (en) The treatment of inflammatory disorders and pain
SI1663287T1 (sl) Uporaba modificiranih ciklosporinov za zdravljenje HCV motenj
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
IL178427A0 (en) 1,2-diarylimidazole-4-carboxamide compounds, processes for their preparation and use thereof in the treatment of obesity, psychiatric and neurological disorders
GB0413077D0 (en) Method of treating parkinson's disease in humans by direct infusion of Glial cell-line derived neurotrophic factor into the Zona incerta
IL174303A0 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
AU2003268484A8 (en) Delivery of therapeutics to the brain and spinal cord
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
IL164240A (en) 1,3,5 - triazine derivatives, compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of parkinson's disease
HK1086194A (en) Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans
IL164951A0 (en) The treatment of pain with lfendropil
GB0419828D0 (en) The treatment of inflammatroy disorders and pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)